Biased Ligands. Better Drugs.

TRV130 Phase 2 abdominoplasty results

A randomized, Phase IIb study investigating oliceridine (TRV130), a novel μ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty

Neil Singla, Harold S Minkowitz, David G Soergel, David A Burt, Ruth Ann Subach, Monica Y Salamea, Michael J Fossler, Franck Skobieranda

View PDF

Copyright © Trevena, Inc.